Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $311,366.64 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 13,017 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.92, for a total transaction of $311,366.64. Following the completion of the sale, the insider directly owned 527,115 shares of the company’s stock, valued at approximately $12,608,590.80. This represents a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total value of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $25.06 on Thursday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The stock has a market capitalization of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. The business has a 50-day moving average price of $22.78 and a two-hundred day moving average price of $22.52.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on KMTS. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, BTIG Research upped their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $27.83.

Institutional Trading of Kestra Medical Technologies

Hedge funds have recently added to or reduced their stakes in the business. Seven Grand Managers LLC bought a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $2,652,000. Eventide Asset Management LLC lifted its stake in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new position in shares of Kestra Medical Technologies in the fourth quarter valued at approximately $9,282,000. UBS Group AG increased its position in shares of Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after acquiring an additional 69,908 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Kestra Medical Technologies by 15.0% during the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after acquiring an additional 28,573 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.